Patient-focused. Driven. Research-led. Takeda Pharmaceuticals has long had one focus – create better health for people and a brighter future for the world. To do that, ensure top-of-the-line facilities and equipment operating and peak output.
Working with McGough and design firm CRB, Takeda took existing facilities and brought them into the future. Making wide-scale additions and demolition to bring their Brooklyn Park facility forward, and with it, driving people’s health worldwide.
This design-build project included process and facility upgrades needed to improve the yield of the biological production. Scope included replacement of vessels, piping and instrumentation. Further, demolition and retrofitting of the facility to produce two different commercial monoclonal antibody products utilizing the large scale for Entyvio® and small-scale train for ADCetris®. The project involved significant rework of piping and electrical systems as well as wall revisions, equipment removal and replacement as necessary for production of the intended biologics. Work also included a chilled water system pipe replacement project and a manufacturing sciences lab project.
Takeda has long relied on the ability of McGough to collaborate, whether under CMAR or design-build project delivery methods. McGough plays an active role in pre-construction planning and constructability, budgeting and permitting. McGough is also keenly aware of how these projects can impact production and advise on phasing that minimizes project risks while allowing beneficial use as soon as possible. McGough also knows the documentation requirements necessary for this FDA-licensed facility. As such, front-end planning is critical to ensuring close-out documents are complete and available at the time of validation.
